Masayuki Yamanouchi

Masayuki Yamanouchi

Auto-generated profile, based on publicly available information

Masayuki Yamanouchi

Nephrology Center, Toranomon Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2021 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
MOMegumi Oshima
Megumi Oshima
MSMiho Shimizu
Miho Shimizu
MYMasayuki Yamanouchi
Masayuki Yamanouchi
TTTadashi Toyama
Tadashi Toyama
AHAkinori Hara
Akinori Hara
TWTakashi Wada
Takashi Wada

1 February 2016 in Kidney International
Verified
Journal Article
Closed access
PDF file
NNNatalia Nowak
Natalia Nowak
JSJan Skupien
Jan Skupien
MNMonika A. Niewczas
Monika A. Niewczas
MYMasayuki Yamanouchi
Masayuki Yamanouchi
MMMelissa Major
Melissa Major
AKAndrzej S. Krolewski
Andrzej S. Krolewski

1 May 2018 in Kidney International
Verified
Journal Article
Closed access
NNNatalia Nowak
Natalia Nowak
JSJan Skupien
Jan Skupien
ASAdam M. Smiles
Adam M. Smiles
MYMasayuki Yamanouchi
Masayuki Yamanouchi
MNMonika A. Niewczas
Monika A. Niewczas
AKAndrzej S. Krolewski
Andrzej S. Krolewski

4 March 2019 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
MYMasayuki Yamanouchi
Masayuki Yamanouchi
KFKengo Furuichi
Kengo Furuichi
JHJunichi Hoshino
Junichi Hoshino
TTTadashi Toyama
Tadashi Toyama
AHAkinori Hara
Akinori Hara
TWTakashi Wada
Takashi Wada
OBJECTIVE Clinicopathological characteristics, renal prognosis, and mortality in patients with type 2 diabetes and reduced renal function without overt proteinuria are scarce. RESEARCH DESIGN AND METHODS We retrospectively assessed 526 patients with type 2 diabetes and reduced renal function (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2), who underwent clinical renal biopsy and had follow-up data, from Japan’s nationwide multicenter renal biopsy registry. For comparative analyses, we derived one-to-two cohorts of those without proteinuria versus those with proteinuria using propensity score–matching methods addressing the imbalances of age, sex, diabetes duration, and baseline eGFR. The primary end point was progression of chronic kidney disease (CKD) defined as new-onset end-stage renal disease, decrease of eGFR by ≥50%, or doubling of serum creatinine. The secondary end point was all-cause mortality. RESULTS Eighty-two patients with nonproteinuria (urine albumin-to-creatinine ratio [UACR] <300 mg/g) had lower systolic blood pressure and less severe pathological lesions compared with 164 propensity score–matched patients with proteinuria (UACR ≥300 mg/g). After a median follow-up of 1.9 years (interquartile range 0.9–5.0 years) from the date of renal biopsy, the 5-year CKD progression-free survival was 86.6% (95% CI 72.5–93.8) for the nonproteinuric group and 30.3% (95% CI 22.4–38.6) for the proteinuric group (log-rank test P < 0.001). The lower renal risk was consistent across all subgroup analyses. The all-cause mortality was also lower in the nonproteinuric group (log-rank test P = 0.005). CONCLUSIONS Patients with nonproteinuric diabetic kidney disease had better-controlled blood pressure and fewer typical morphological changes and were at lower risk of CKD progression and all-cause mortality.

31 March 2020 in Clinical and Experimental Nephrology
Verified
Journal Article
Open access
PDF file
MYMasayuki Yamanouchi
Masayuki Yamanouchi
KFKengo Furuichi
Kengo Furuichi
JHJunichi Hoshino
Junichi Hoshino
YUYoshifumi Ubara
Yoshifumi Ubara
TWTakashi Wada
Takashi Wada
Proteinuria has been considered to be the hallmark of diabetic kidney disease and to precede renal function loss. However, it has become clear that a substantial proportion of patients either with type 1 diabetes or type 2 diabetes have renal function loss without proteinuria, known as nonproteinuric diabetic kidney disease. Despite increasing recognition of the prevalence of nonproteinuric diabetic kidney disease, data on this phenotype of diabetic kidney disease is sparse. This review describes ever known clinical and pathological manifestations, renal prognosis, and mortality in patient with nonproteinuric diabetic kidney disease.

2 November 2019 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
MYMasayuki Yamanouchi
Masayuki Yamanouchi
MMMikiro Mori
Mikiro Mori
JHJunichi Hoshino
Junichi Hoshino
KKKeiichi Kinowaki
Keiichi Kinowaki
TFTakeshi Fujii
Takeshi Fujii
YUYoshifumi Ubara
Yoshifumi Ubara
Objective: The predictive value of diabetic retinopathy on end-stage kidney disease (ESKD) has not been fully addressed in patients with type 2 diabetes and diabetic kidney disease. Research design and methods: We studied 232 patients with type 2 diabetes and biopsy-proven diabetic kidney disease who were screened for diabetic retinopathy during the 1 month of kidney biopsy. We examined the association between retinopathy progression and renal lesions. We used Cox regression analyses to explore the risk of ESKD adjusting for known risk demographic and clinical variables. We assessed the incremental prognostic value of ESKD by adding diabetic retinopathy to the clinical variables. Results: The diabetic retinopathy progression positively correlated with all scores of renal lesions, especially with the glomerular-based classification (r=0.41), scores of interstitial fibrosis (r=0.41) and diffuse lesion (r=0.48). During a median follow-up of 5.7 years, 114 patients developed ESKD. Adjusting for known risk factors of ESKD, the HR for ESKD (patients with no apparent retinopathy as a reference) were 1.96 (95% CI 0.62 to 6.17) for patients with mild non-proliferative diabetic retinopathy (NPDR), 3.10 (95% CI 1.45 to 6.65) for patients with moderate NPDR, 3.03 (95% CI 1.44 to 6.37) for patients with severe NPDR, and 3.43 (95% CI 1.68 to 7.03) for patients with proliferative diabetic retinopathy, respectively. Addition of the retinopathy grading to the clinical model alone improved the prognostic value (the global χ2 statistic increased from 155.2 to 164.5; p<0.001), which is an improvement equivalent to the addition of the renal lesion grading to the clinical model. Conclusions: Retinopathy progression appeared to be associated with renal lesions and the development of ESKD. Our findings suggest that diabetic retinopathy and kidney disease share the same magnitude of disease progression, and therefore diabetic retinopathy may be useful for prognosticating the clinical course for diabetic kidney disease.